Methods
We performed a single center IRB approved retrospective chart review of 80 consecutive pediatric allogeneic SCT patients transplanted between 2013 and 2015. Clinical data was reviewed through 2019. Baseline hyperfiltration status was determined using pre-SCT nuclear medicine GFR. Hyperfiltration was defined as a GFR≥135 mL/min/1.73 m2, which is the median value used in the literature.6 A normal GFR was defined as a GFR between 90 and 135 mL/min/1.73 m2. Demographics recorded included age, gender, primary diagnosis, exposure to chemotherapy prior to SCT, stem cell source and match, conditioning regimen, and if ex-vivo T cell depletion was utilized for graft versus host prevention. Outcomes assessed included AKI, defined as a doubling of creatinine in the first 100 days of transplant, need for renal replacement therapy, and 1 year event-free survival. In patients who had at least 2 years of follow up, the outcome of CKD was defined as a creatinine-based estimated GFR<90 or GFR≥135 mL/min/1.73 m2 at last follow up. Continuous and categorical data were summarized as median (interquartile range) and frequency (percent), respectively. Continuous data were assessed between hyperfiltration (Y/N) patients using a Wilcoxon rank sum test. Categorical data were compared between hyperfiltration patients using Fisher’s exact test. A p-value of <0.05 was considered significant.